Saltar al contenido
Merck

Chronic pelvic allodynia is mediated by CCL2 through mast cells in an experimental autoimmune cystitis model.

American journal of physiology. Renal physiology (2014-09-12)
Fuat Bicer, Cengiz Z Altuntas, Kenan Izgi, Ahmet Ozer, Michael Kavran, Vincent K Tuohy, Firouz Daneshgari
RESUMEN

The cause of chronic pelvic pain in interstitial cystitis/painful bladder syndrome (IC/PBS) remains unclear; autoimmunity is a possible etiology. We have recently shown that injection of a single immunogenic peptide of uroplakin 3A (UPK3A 65-84) induces experimental autoimmune cystitis (EAC) in female BALB/cJ mice that is unique among experimental models in accurately reflecting both the urinary symptoms and pelvic pain of IC/PBS. The aim of this project was to identify the roles of mast cells and mast cell chemoattractant/activator monocyte chemoattractant protein-1 [chemokine (C-C motif) ligand 2 (CCL2)] in the allodynia in this model. We immunized 6- to 8-wk-old female BALB/cJ mice with UPK3A 65-84 peptide and, 5-40 days later, observed increased responses to stimulation of the suprapubic abdominal and hindpaw surfaces with von Frey monofilaments compared with mice injected with adjuvant alone. Suprapubic and hindpaw tactile allodynia responses by EAC mice were blocked by instillation of lidocaine into the bladder but not by lidocaine in the uterus, confirming the bladder as the source of the hypersensitivity. Markedly increased numbers of activated mast cells and expression of CCL2 were found in the bladder after immunization with UPK3A 65-84. Hypersensitive responses were inhibited by mast cell stabilizer cromolyn sodium and antagonists of histamine receptors 1 and 2. Furthermore, BALB/cJ mice with deletion of the Ccl2 or chemokine (C-C motif) receptor 2 gene exhibited markedly reduced allodynia and accumulation of mast cells after UPK3A 65-84 immunization. These results show that UPK3A 65-84 immunization causes chronic visceral allodynia and suggest that it is mediated by CCL2-driven mast cell accumulation in the bladder.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Lidocaine, powder
Sigma-Aldrich
Histamine, ≥97.0%
USP
Lidocaine, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Cetirizine dihydrochloride, ≥98% (HPLC)
Sigma-Aldrich
Ranitidine hydrochloride, solid
Supelco
Lidocaine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Lidocaine, analytical standard
Sigma-Aldrich
Cromolyn sodium salt, ≥95%
Sigma-Aldrich
Cetirizin dihydrochloride, ≥98.0% (HPLC)
Supelco
Histamine, analytical standard
USP
Ranitidine hydrochloride, United States Pharmacopeia (USP) Reference Standard
Cetirizine dihydrochloride, European Pharmacopoeia (EP) Reference Standard
Supelco
Ranitidine hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Isoflurane, European Pharmacopoeia (EP) Reference Standard
Cetirizine dihydrochloride, European Pharmacopoeia (EP) Reference Standard
Lidocaine, European Pharmacopoeia (EP) Reference Standard
Sodium cromoglicate, European Pharmacopoeia (EP) Reference Standard
Sodium cromoglicate for system suitability, European Pharmacopoeia (EP) Reference Standard
Ranitidine hydrochloride, European Pharmacopoeia (EP) Reference Standard